We used G-CSF-primed PBSC as the sole source of stem cells in a patient allografted after high-dose busulfan alone due to the occurrence of septic shock during conditioning. A 44-year-old woman with AML, while receiving a conditioning treatment with BU-CY for an allogeneic sibHematologic recovery was fast and complete. The microsatellite DNA analysis confirms that engraftment is ling transplant, developed septic shock with pulmonary embolism and heart failure. Conditioning was stopped of full donor origin. at the end of the busulfan course and cyclophosphamide omitted. After antibiotics, dopamine and steroids the patient was allografted, using the donor's G-CSFCase report primed PBSC. She recovered her peripheral blood counts promptly and developed an acute GVHD grade A 44-year-old woman was diagnosed with AML (M2, FAB) and obtained a complete remission after a single II that responded to steroids. The DNA microsatellite analysis showed full donor engraftment up to a year course of chemotherapy with idarubicin 10 mg/m 2 /day i.v., days 1, 3, 5; Ara-C 125 mg/m 2 /day, continuous infusion, from transplantation. This case suggests that the use of PBSC may facilitate engraftment in the absence of an days 1-10 and VP-16 100 mg/m 2 /day i.v., days 1-5. Following a single consolidation course with Ara-C effective immunosuppression during conditioning. Keywords: conditioning; busulfan; PBSC; transplan-1 g/m 2 /day, continuous infusion, days 1-6 and idarubicin 10 mg/m 2 /day i.v., days 4-6, she was planned for an allotation; chimerism geneic transplant from her HLA-identical sister. The patient was admitted to the transplant unit 5 months after CR was obtained. Pretransplant evaluation showed The success of allogeneic marrow transplantation across normal findings. She received a subcutaneous i.v. central major and minor histocompatibility barriers requires effecline through the cephalic vein and was started on the BUtive immunosuppression of the host. Conditioning regimens CY conditioning regimen (busulfan 4 mg/kg/day, days −9 including TBI and high-dose cyclophosphamide are comto −6; cyclophosphamide 50 mg/kg/day, days −5 to −2). monly used for this purpose, but the chemotherapy combiHowever, on day −6, before receiving the last two busulfan nation of busulfan and cyclophosphamide can effectively doses, she developed chills and fever up to 40°C. The picreplace TBI regimens.
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1,2 However, busulfan itself has little ture rapidly evolved with hypotension, oliguria and shock if any immunosuppressive effect, 3 and the literature lacks and the patient was referred to the intensive care unit, any evidence of successful alloengraftment after conditionwhere her cardiac function rapidly declined, with right vening with busulfan alone. tricular failure and fluid retention. The echodoppler sonoThe alloengraftment process depends also on the number graphy and the lung scintigraphy revealed a picture of puland quality of cells in the inoculum.
4 Growth factor-mobilmonary embolism. The conditioning was therefore stopped. ized PBSC exhibit an engraftment potential superior to that Treatment with antibiotics, high-dose steroids and dopaof marrow, as shown by their ability to accelerate hematomine was immediately instituted. A total of 2 g hydrocortipoietic recovery 5 and to rescue patients with graft failure. 6 sone and 5 g 6-methylprednisolone were given over 3 days. Recent data 7 also suggest that PBSC, with their high proThe culture of the atrial catheter tip grew Enterobacter genitor cell content, may help to overcome the genetic discloacae, sensitive in vitro to currently given antibiotics. parity in HLA-haploidentical pair transplants. There is now Two days later, having rescued a better cardiac and circulatevidence coming from molecular studies that allogeneic ory function, the patient was again transferred to the trans-PBSC ensure a stable donor take in the host. 8, 9 plant unit. Her HLA-identical sister consented to PBSC instead of bone marrow donation and was therefore started on G-CSF 10 g/kg/day for 5 days, to mobilize PBSC. She The first two aphereses were kept at 4°C and infused ium bromide and the bands were directly visualized under UV. Results of chimerism studies are reported in Figure 1 . together into the patient over a 3-h period, while the third apheresis product was cryopreserved as back-up. In this They show early myeloid engraftment, with mixed lymphoid chimerism transiently appearing 75 days post-graft. case, the day of infusion followed the last busulfan administration by 6 days. The infusion product contained
The follow-up DNA study shows a full myeloid and lymphoid engraftment up to 360 days from transplantation. /kg CD19 + cells. CsA was given from day −1, 2 mg/kg in two Discussion divided 4-h i.v. infusions; methotrexate was given on day +1, +3, +6, +11 at the dose of 15, 10, 10, 10 mg/m 2 respectIn the case presented here, rapid and stable engraftment was obtained with the infusion of allogeneic PBSC after ively. From day +1 the patient also received GM-CSF 5 g/kg/day. Apart from a 3-day duration, rapidly conditioning with busulfan alone. As shown by the molecular analysis, donor chimerism was established early, and responding fever with no isolation, the immediate post-graft course was uneventful, and mucositis remarkably mild. The persisted during the months that followed the graft. The same studies done on the selected CD3 + cell population transfusional support consisted of two packed red cell units and two single-donor platelet units. The patient also showed a mixed T cell chimera only transiently, suggesting the persistence of the host immune system shortly after received granulocyte transfusions on days +5, +7, +11 and +12. All the blood products were irradiated (25 Gy). The PBSC allogeneic transplantation. What clinical implications this may have is difficult to say. A mixed T cell lymphoid blood counts recovered rapidly after transplantation, with ANC Ͼ0.5 × 10 9 /l on day +12, ANC Ͼ1 × 10 9 /l on day chimerism in the presence of donor granulocyte engraftment has been associated with increased risk of dis-+14, platelets Ͼ50 × 10 9 /l on day +12. On day +16 the patient developed signs of GVHD, grade II (skin and gut) ease recurrence in the long term follow-up, 10 but in our patient serial studies showed the establishment with time and was started on 6-methylprednisolone 2 mg/kg for 5 days. The dose was thereafter halved by 10 days and of a fully donor-derived lymphoid system. The alkylating agent busulfan was introduced into the stopped on day +63. On day +160, while on cyclosporine, she developed limited hepatic cGVHD. The patient is curconditioning preparations for its unique capacity of ablating pluripotent stem cells. 1 However, early experiments in anirently alive with only mild cGVHD and free of disease at 1 year after transplantation. mals transplanted after conditioning with busulfan alone were characterized by prompt rejection. 3 In fact busulfan For molecular studies, bone marrow and peripheral blood were examined at different times after transplantation. To is devoid of an immunosuppressive effect, and it is necessary to have an association of cyclophosphamide or antidetermine the lymphoid chimerism, CD3
+ cells were selected from peripheral blood using the immunomagnetic CD3 thymocyte globulin to obtain a marrow take in the animal. In man, Santos et al 1 introduced the radiation-free regimicrobeads (MACS; Miltenyi Biotec, CA, USA) and separated in the presence of a magnet. Amplification of DNA men consisting of busulfan and 200 mg/kg cyclophosphamide, showing excellent engraftment data. An attempt to microsatellite (CA repeats) was carried out using specific primers for D5S421. PCR was performed as previously reduce treatment toxicity led to a reduction of cyclophosphamide to 120 mg/kg, 2 but did not result in rejection or in described.
9 For the analysis of PCR products, 10 l of the reaction mixture was electrophoresed through a 6% polyacincreased leukemia relapse. A successful attempt to further reduce the dose of cyclophosphamide in the BU-CY combirylamide gel, running at 200 V for 3-4 h stained with ethid-
